Hemophagocytic Lymphohistiocytosis/Hemophagocytic Syndromes

  • Roberto N. Miranda
  • Joseph D. Khoury
  • L. Jeffrey Medeiros
Part of the Atlas of Anatomic Pathology book series (AAP)


A hemophagocytic syndrome is a systemic, non-neoplastic acute disease presenting with cytopenias and organ infiltration by histiocytes, frequently with hemophagocytosis, and is usually fatal if left untreated.

The term hemophagocytic lymphohistiocytosis (HLH) is used to include primary or familial and secondary causes of hemophagocytic syndromes. The overall incidence is approximately 1.2 in 1 million individuals per year. Primary HLH occurs due to various gene abnormalities affecting apoptosis and usually manifests during infancy or early childhood, and rarely in adulthood. Gene mutations affect cytotoxic cell function and are inherited as autosomal recessive.

Secondary HLH, which is the focus of this chapter, most often affects older children and adults, but also can affect young children. Underlying causes are infections, malignancy, metabolic, or rheumatologic conditions, and immunodeficiency. Associated infections that trigger the syndrome include Epstein-Barr virus (EBV), herpes simplex virus, human immunodeficiency virus (HIV), and cytomegalovirus. Rheumatologic diseases include rheumatoid arthritis, systemic lupus erythematosus, Still disease, and Kawasaki syndrome. Malignancies include acute leukemia and myelodysplastic syndromes, T/NK-cell lymphoma/leukemia, B-cell lineage leukemias, and lymphomas such as intravascular B-cell lymphoma. Immunodeficiency states include infection with human immunodeficiency virus, iatrogenic, or after organ transplantation.


Human Immunodeficiency Virus Systemic Lupus Erythematosus Acute Leukemia Infectious Mononucleosis Macrophage Activation Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Gaffey MJ, Frierson Jr HF, Medeiros LJ, Weiss LM. The relationship of Epstein-Barr virus to infection-related (sporadic) and familial hemophagocytic syndrome and secondary (lymphoma-related) hemophagocytosis: an in situ hybridization study. Hum Pathol. 1993;24:657–67.PubMedCrossRefGoogle Scholar
  3. 3.
    Atteritano M, David A, Bagnato G, et al. Haemophagocytic syndrome in rheumatic patients. A systematic review. Eur Rev Med Pharmacol Sci. 2012;16:1414–24.PubMedGoogle Scholar
  4. 4.
    Fung KM, Chakrabarty JH, Kern WF, et al. Intravascular large B-cell lymphoma with hemophagocytic syndrome (Asian variant) in a Caucasian patient. Int J Clin Exp Pathol. 2012;5:448–54.PubMedGoogle Scholar
  5. 5.
    Wang SA. Lymphohistiocytic hemophagocytosis. In: Medeiros LJ, editor. Diagnostic pathology: lymph nodes and spleen with extranodal sites. 1st ed. Altona: Amirsys; 2011. p. 3-78–87.Google Scholar
  6. 6.
    Sumegi J, Barnes MG, Nestheide SV, et al. Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis. Blood. 2011;117:e151–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Weitzman S. Approach to hemophagocytic syndromes. Hematology Am Soc Hematol Educ Program. 2011;2011:178–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Ramanan AV, Baildam EM. Macrophage activation syndrome is hemophagocytic lymphohistiocytosis—need for the right terminology. J Rheumatol. 2002;29:1105; author reply.PubMedGoogle Scholar
  9. 9.
    Grom AA. Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol. 2003;15:587–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Schaer DJ, Schleiffenbaum B, Kurrer M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. 2005;74:6–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Bode SF, Lehmberg K, Maul-Pavicic A, et al. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthritis Res Ther. 2012;14:213.PubMedCrossRefGoogle Scholar
  12. 12.
    Kleynberg RL, Schiller GJ. Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin Adv Hematol Oncol. 2012;10:726–32.PubMedGoogle Scholar
  13. 13.
    Milone MC, Tsai DE, Hodinka RL, et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood. 2005;105:994–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Roberto N. Miranda
    • 1
  • Joseph D. Khoury
    • 1
  • L. Jeffrey Medeiros
    • 1
  1. 1.Department of HematopathologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations